Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling

BACKGROUND: Gambogic acid (GA) has been reported to have potent anticancer activity and is authorised to be tested in phase II clinical trials for treatment of non-small-cell lung cancer (NSCLC). The present study aims to investigate whether GA would be synergistic with cisplatin (CDDP) against the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, L-H, Li, Y, Yang, S-N, Wang, F-Y, Hou, Y, Cui, W, Chen, K, Cao, Q, Wang, S, Zhang, T-Y, Wang, Z-Z, Xiao, W, Yang, J-Y, Wu, C-F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899775/
https://www.ncbi.nlm.nih.gov/pubmed/24300974
http://dx.doi.org/10.1038/bjc.2013.752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899775/
https://www.ncbi.nlm.nih.gov/pubmed/24300974
http://dx.doi.org/10.1038/bjc.2013.752

Ejemplares similares